TCT-251 Abnormal glucose metabolism and adverse event rates 12 months after treatment with contemporary drug-eluting stents: Insights from the BIO-RESORT Silent Diabetes study

Marlies Kok, Clemens von Birgelen, Paolo Zocca, Marc Hartmann, K. Gert van Houwelingen, Martin Stoel, Frits de Man, J.Hans Louwerenburg, Marije Lowik, Gert Kant, Cees Doelman, Gerard C.M. Linssen, Liefke van der Heijden, Carine J.M. Doggen, Kenneth Tandjung

Research output: Contribution to journalArticleAcademic

Abstract

BACKGROUND: Patients with abnormal glucose metabolism, including patients with undetected and thus untreated diabetes, may have higher event risks after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES). We assessed the prevalence and clinical impact of abnormal glucose metabolism in allcomer patients without previously known diabetes undergoing PCI.

METHODS: The BIO-RESORT Silent Diabetes study, performed at Thoraxcentrum Twente, is a substudy of the randomized BIO-RESORT trial (NCT01674803). We performed an additional analysis identifying patients with an abnormal glucose metabolism by means of oral glucose tolerance testing (OGTT), and assessment of glycated hemoglobin A1c (HbA1c) with fasting plasma glucose (FPG) and clinical outcome at 12 months.

RESULTS: Assessment of glucose metabolism revealed that of the 988 participants a total 330 (33.4%) patients had an abnormal metabolism, while 658 (66.6%) patients had a normal metabolism. Patients with abnormal glucose metabolism showed higher rates of the primary endpoint Target Vessel Failure (6.4% vs. 2.7%; p0.01), a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization. Multivariate analysis demonstrated that an abnormal glucose metabolism independently predicted adverse event risk (HR 2.2, 95%-CI:1.2-4.2).

CONCLUSION: Abnormal glucose metabolism was detected in one out of three PCI all-comer patients and independently associated with a more than 2-fold higher event risk. Future intervention studies should determine whether meaningful benefits may accrue from routine glycaemia testing in such patients.
Original languageEnglish
Pages (from-to)B104-B104
JournalJournal of the American College of Cardiology
Volume70
Issue number18, Supplement
DOIs
Publication statusPublished - Oct 2017
Event29th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2017 - Denver, United States
Duration: 29 Oct 20172 Nov 2017
Conference number: 29

Fingerprint

Drug-Eluting Stents
Glucose
Percutaneous Coronary Intervention
Therapeutics
Glycosylated Hemoglobin A
Glucose Tolerance Test
Fasting
Multivariate Analysis
Myocardial Infarction

Cite this

Kok, Marlies ; von Birgelen, Clemens ; Zocca, Paolo ; Hartmann, Marc ; Gert van Houwelingen, K. ; Stoel, Martin ; de Man, Frits ; Louwerenburg, J.Hans ; Lowik, Marije ; Kant, Gert ; Doelman, Cees ; Linssen, Gerard C.M. ; van der Heijden, Liefke ; Doggen, Carine J.M. ; Tandjung, Kenneth. / TCT-251 Abnormal glucose metabolism and adverse event rates 12 months after treatment with contemporary drug-eluting stents : Insights from the BIO-RESORT Silent Diabetes study. In: Journal of the American College of Cardiology. 2017 ; Vol. 70, No. 18, Supplement. pp. B104-B104.
@article{25eef189345545dea550a7bf61aebcc8,
title = "TCT-251 Abnormal glucose metabolism and adverse event rates 12 months after treatment with contemporary drug-eluting stents: Insights from the BIO-RESORT Silent Diabetes study",
abstract = "BACKGROUND: Patients with abnormal glucose metabolism, including patients with undetected and thus untreated diabetes, may have higher event risks after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES). We assessed the prevalence and clinical impact of abnormal glucose metabolism in allcomer patients without previously known diabetes undergoing PCI.METHODS: The BIO-RESORT Silent Diabetes study, performed at Thoraxcentrum Twente, is a substudy of the randomized BIO-RESORT trial (NCT01674803). We performed an additional analysis identifying patients with an abnormal glucose metabolism by means of oral glucose tolerance testing (OGTT), and assessment of glycated hemoglobin A1c (HbA1c) with fasting plasma glucose (FPG) and clinical outcome at 12 months.RESULTS: Assessment of glucose metabolism revealed that of the 988 participants a total 330 (33.4{\%}) patients had an abnormal metabolism, while 658 (66.6{\%}) patients had a normal metabolism. Patients with abnormal glucose metabolism showed higher rates of the primary endpoint Target Vessel Failure (6.4{\%} vs. 2.7{\%}; p0.01), a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization. Multivariate analysis demonstrated that an abnormal glucose metabolism independently predicted adverse event risk (HR 2.2, 95{\%}-CI:1.2-4.2).CONCLUSION: Abnormal glucose metabolism was detected in one out of three PCI all-comer patients and independently associated with a more than 2-fold higher event risk. Future intervention studies should determine whether meaningful benefits may accrue from routine glycaemia testing in such patients.",
author = "Marlies Kok and {von Birgelen}, Clemens and Paolo Zocca and Marc Hartmann and {Gert van Houwelingen}, K. and Martin Stoel and {de Man}, Frits and J.Hans Louwerenburg and Marije Lowik and Gert Kant and Cees Doelman and Linssen, {Gerard C.M.} and {van der Heijden}, Liefke and Doggen, {Carine J.M.} and Kenneth Tandjung",
year = "2017",
month = "10",
doi = "10.1016/j.jacc.2017.09.324",
language = "English",
volume = "70",
pages = "B104--B104",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier",
number = "18, Supplement",

}

Kok, M, von Birgelen, C, Zocca, P, Hartmann, M, Gert van Houwelingen, K, Stoel, M, de Man, F, Louwerenburg, JH, Lowik, M, Kant, G, Doelman, C, Linssen, GCM, van der Heijden, L, Doggen, CJM & Tandjung, K 2017, 'TCT-251 Abnormal glucose metabolism and adverse event rates 12 months after treatment with contemporary drug-eluting stents: Insights from the BIO-RESORT Silent Diabetes study', Journal of the American College of Cardiology, vol. 70, no. 18, Supplement, pp. B104-B104. https://doi.org/10.1016/j.jacc.2017.09.324

TCT-251 Abnormal glucose metabolism and adverse event rates 12 months after treatment with contemporary drug-eluting stents : Insights from the BIO-RESORT Silent Diabetes study. / Kok, Marlies; von Birgelen, Clemens; Zocca, Paolo; Hartmann, Marc; Gert van Houwelingen, K.; Stoel, Martin; de Man, Frits; Louwerenburg, J.Hans; Lowik, Marije; Kant, Gert; Doelman, Cees; Linssen, Gerard C.M.; van der Heijden, Liefke; Doggen, Carine J.M.; Tandjung, Kenneth.

In: Journal of the American College of Cardiology, Vol. 70, No. 18, Supplement, 10.2017, p. B104-B104.

Research output: Contribution to journalArticleAcademic

TY - JOUR

T1 - TCT-251 Abnormal glucose metabolism and adverse event rates 12 months after treatment with contemporary drug-eluting stents

T2 - Insights from the BIO-RESORT Silent Diabetes study

AU - Kok, Marlies

AU - von Birgelen, Clemens

AU - Zocca, Paolo

AU - Hartmann, Marc

AU - Gert van Houwelingen, K.

AU - Stoel, Martin

AU - de Man, Frits

AU - Louwerenburg, J.Hans

AU - Lowik, Marije

AU - Kant, Gert

AU - Doelman, Cees

AU - Linssen, Gerard C.M.

AU - van der Heijden, Liefke

AU - Doggen, Carine J.M.

AU - Tandjung, Kenneth

PY - 2017/10

Y1 - 2017/10

N2 - BACKGROUND: Patients with abnormal glucose metabolism, including patients with undetected and thus untreated diabetes, may have higher event risks after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES). We assessed the prevalence and clinical impact of abnormal glucose metabolism in allcomer patients without previously known diabetes undergoing PCI.METHODS: The BIO-RESORT Silent Diabetes study, performed at Thoraxcentrum Twente, is a substudy of the randomized BIO-RESORT trial (NCT01674803). We performed an additional analysis identifying patients with an abnormal glucose metabolism by means of oral glucose tolerance testing (OGTT), and assessment of glycated hemoglobin A1c (HbA1c) with fasting plasma glucose (FPG) and clinical outcome at 12 months.RESULTS: Assessment of glucose metabolism revealed that of the 988 participants a total 330 (33.4%) patients had an abnormal metabolism, while 658 (66.6%) patients had a normal metabolism. Patients with abnormal glucose metabolism showed higher rates of the primary endpoint Target Vessel Failure (6.4% vs. 2.7%; p0.01), a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization. Multivariate analysis demonstrated that an abnormal glucose metabolism independently predicted adverse event risk (HR 2.2, 95%-CI:1.2-4.2).CONCLUSION: Abnormal glucose metabolism was detected in one out of three PCI all-comer patients and independently associated with a more than 2-fold higher event risk. Future intervention studies should determine whether meaningful benefits may accrue from routine glycaemia testing in such patients.

AB - BACKGROUND: Patients with abnormal glucose metabolism, including patients with undetected and thus untreated diabetes, may have higher event risks after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES). We assessed the prevalence and clinical impact of abnormal glucose metabolism in allcomer patients without previously known diabetes undergoing PCI.METHODS: The BIO-RESORT Silent Diabetes study, performed at Thoraxcentrum Twente, is a substudy of the randomized BIO-RESORT trial (NCT01674803). We performed an additional analysis identifying patients with an abnormal glucose metabolism by means of oral glucose tolerance testing (OGTT), and assessment of glycated hemoglobin A1c (HbA1c) with fasting plasma glucose (FPG) and clinical outcome at 12 months.RESULTS: Assessment of glucose metabolism revealed that of the 988 participants a total 330 (33.4%) patients had an abnormal metabolism, while 658 (66.6%) patients had a normal metabolism. Patients with abnormal glucose metabolism showed higher rates of the primary endpoint Target Vessel Failure (6.4% vs. 2.7%; p0.01), a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization. Multivariate analysis demonstrated that an abnormal glucose metabolism independently predicted adverse event risk (HR 2.2, 95%-CI:1.2-4.2).CONCLUSION: Abnormal glucose metabolism was detected in one out of three PCI all-comer patients and independently associated with a more than 2-fold higher event risk. Future intervention studies should determine whether meaningful benefits may accrue from routine glycaemia testing in such patients.

UR - http://www.mendeley.com/research/tct251-abnormal-glucose-metabolism-adverse-event-rates-12-months-after-treatment-contemporary-drugel

U2 - 10.1016/j.jacc.2017.09.324

DO - 10.1016/j.jacc.2017.09.324

M3 - Article

VL - 70

SP - B104-B104

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 18, Supplement

ER -